Trial Profile
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Duloxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- 01 May 2023 Results of pooled analysis from NCT01140906, NCT01153009, NCT01163266, NCT01255787, NCT01488071, published in the Journal of Affective Disorders
- 01 Sep 2015 Results of meta analysis of pooled data from 9 trials presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
- 18 May 2013 Results presented at 166th Annual American Psychiatric Association Meeting, according to Takeda Pharmaceutical Company and Lundbeck media release.